Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.

Barch DM, Carter CS; CNTRICS Executive Committee.

Schizophr Bull. 2008 Jul;34(4):613-8. doi: 10.1093/schbul/sbn037. Epub 2008 May 21.

PMID:
18499705
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.

Keefe RS, Harvey PD.

Schizophr Bull. 2008 Jul;34(4):656-63. doi: 10.1093/schbul/sbn042. Epub 2008 May 20. Review.

PMID:
18495645
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The translation of cognitive paradigms for patient research.

Luck SJ, Gold JM.

Schizophr Bull. 2008 Jul;34(4):629-44. doi: 10.1093/schbul/sbn036. Epub 2008 May 16.

PMID:
18487226
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Building a clinically relevant cognitive task: case study of the AX paradigm.

MacDonald AW 3rd.

Schizophr Bull. 2008 Jul;34(4):619-28. doi: 10.1093/schbul/sbn038. Epub 2008 May 16. Review.

PMID:
18487225
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Implications of clinical trial design on sample size requirements.

Leon AC.

Schizophr Bull. 2008 Jul;34(4):664-9. doi: 10.1093/schbul/sbn035. Epub 2008 May 9. Review.

PMID:
18469326
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.

Silverstein SM.

Schizophr Bull. 2008 Jul;34(4):645-55. doi: 10.1093/schbul/sbn032. Epub 2008 May 8. Review.

PMID:
18468987
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R.

Biol Psychiatry. 2008 Jul 1;64(1):4-10. doi: 10.1016/j.biopsych.2008.03.020. Epub 2008 May 7.

PMID:
18466880
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.

Carter CS, Barch DM.

Schizophr Bull. 2007 Sep;33(5):1131-7. Epub 2007 Jul 14. Review.

PMID:
17630405
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006 Sep;67(9):e11. Review.

PMID:
17081078
[PubMed - indexed for MEDLINE]
11.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
[PubMed - indexed for MEDLINE]
12.

Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.

Lewis DA, Volk DW, Hashimoto T.

Psychopharmacology (Berl). 2004 Jun;174(1):143-50. Epub 2003 Dec 9. Review.

PMID:
15205885
[PubMed - indexed for MEDLINE]
13.

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Martin LF, Kem WR, Freedman R.

Psychopharmacology (Berl). 2004 Jun;174(1):54-64. Epub 2004 Feb 19. Review.

PMID:
15205879
[PubMed - indexed for MEDLINE]
14.

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Friedman JI.

Psychopharmacology (Berl). 2004 Jun;174(1):45-53. Epub 2004 Feb 19. Review.

PMID:
15205878
[PubMed - indexed for MEDLINE]
15.

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.

Moghaddam B.

Psychopharmacology (Berl). 2004 Jun;174(1):39-44. Epub 2004 Feb 19. Review.

PMID:
15205877
[PubMed - indexed for MEDLINE]
16.

Adrenergic targets for the treatment of cognitive deficits in schizophrenia.

Arnsten AF.

Psychopharmacology (Berl). 2004 Jun;174(1):25-31. Epub 2003 Dec 19. Review.

PMID:
15205875
[PubMed - indexed for MEDLINE]
17.

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Roth BL, Hanizavareh SM, Blum AE.

Psychopharmacology (Berl). 2004 Jun;174(1):17-24. Epub 2003 Dec 2. Review.

PMID:
15205874
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk